LatestDACO Warns Against Price Gouging on Water Cistern Services
Cannabis

The Entourage Effect Tackles Pain: Science Proves Cannabinoid and Terpene Synergy in Sensory Neurons

The Entourage Effect Tackles Pain: Science Proves Cannabinoid and Terpene Synergy in Sensory Neurons
Chronic Pain
Summary

Groundbreaking research from Sussex, UCL, and 113 Botanicals provides direct electrophysiological evidence that cannabis compounds work synergistically to reduce pain signals. The study demonstrates how primary phytocannabinoids (CBD and THC) combined with specific terpenes (myrcene, linalool, and alpha-pinene) create a quantifiable entourage effect by directly inhibiting sensory neuron excitability in dorsal root ganglia. This discovery offers a compelling non-opioid alternative for chronic and neuropathic pain management, addressing the opioid crisis while providing scientific validation for whole-plant cannabis therapeutics.

Originally published on

Soft Secrets (Español)

Read full article(opens in new tab)

Fetched: August 7, 2026 at 10:02 AM

Related News

More news you might be interested in

View all
Cannabis

Puerto Rico Orders Evaluation of Emerging Therapy Pilot Program

Governor Jenniffer González has signed an executive order directing the evaluation of a clinical research pilot program focused on emerging therapeutic approaches in Puerto Rico. The initiative establishes explicit limitations on therapeutic use while advancing scientific investigation into novel treatment options. This regulatory framework aims to balance innovation with patient safety and evidence-based medical practice. The pilot program represents Puerto Rico's commitment to exploring cutting-edge therapies that may benefit residents with various health conditions. The evaluation process will provide crucial data to inform future therapeutic protocols and policy decisions across the island.

8 hours ago
Cannabis Magazine
Cannabis
DepressionMajor Depressive Disorder

Psilocybin Shows Initial Efficacy in Treatment-Resistant Depression

A British NHS clinical trial involving 60 participants has demonstrated that psilocybin, a naturally occurring psychedelic compound, shows promise in treating treatment-resistant depression—cases where standard antidepressants have failed. Participants receiving psilocybin-assisted therapy experienced significant improvements compared to placebo controls. However, researchers emphasize the need for larger confirmatory studies before clinical recommendations can be made. This finding represents an important development in psychiatric research, as treatment-resistant depression affects millions globally and leaves patients with limited therapeutic options. The results suggest psilocybin may offer a novel mechanism of action for severe depressive disorders.

8 hours ago
Cannabis Magazine
MJBizDaily
Cannabis

Another Colorado Cannabis Cultivation Operation Shuts Down Following Verdant Acquisition

Verdant, a cannabis investment and operations platform, has completed its acquisition of Native Roots stores as of July 31, resulting in layoffs at a Colorado cultivation facility. This shutdown reflects ongoing consolidation in the cannabis industry as larger platforms acquire and restructure smaller operations. Such business transitions can impact patients' access to consistent cannabis products and cultivar availability. The acquisition highlights how investment-driven consolidation is reshaping Colorado's cannabis market landscape.

14 hours ago
MJBizDaily
Germany's Cannabis Club Licensing Crisis Threatens Medical Patient Access
Cannabis
CancerChronic Pain

Germany's Cannabis Club Licensing Crisis Threatens Medical Patient Access

Germany's ambitious cannabis social club licensing program faces significant implementation challenges, with less than 60% of nearly 900 applications approved as clubs struggle with regulatory hurdles, location restrictions, and financial barriers. Simultaneously, medical cannabis patients confront new reimbursement restrictions from insurance providers that could force tens of thousands to discontinue treatment, pay out-of-pocket, or seek alternative therapies. The dual crisis reflects tensions between Germany's decriminalization efforts and practical enforcement inconsistencies across regions. These policy reversals particularly impact patients treating chronic conditions who previously accessed cannabis through medical channels. The situation highlights ongoing gaps between legislative intent and real-world implementation in European cannabis regulation.

15 hours ago
High Times